Novartis AG (NOVN)

Currency in CHF
92.29
-1.05(-1.12%)
Closed·
NOVN Scorecard
Full Analysis
Management has been aggressively buying back shares
NOVN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
91.9493.03
52 wk Range
81.10102.72
Key Statistics
Bid/Ask
92.29 / 93.50
Prev. Close
93.34
Open
92.35
Day's Range
91.94-93.03
52 wk Range
81.1-102.72
Volume
3.76M
Average Volume (3m)
3.23M
1-Year Change
-5.77%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
NOVN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
97.47
Upside
+5.61%
Members' Sentiments
Bearish
Bullish
ProTips
High shareholder yield

Novartis AG News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still’s disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

Employees
75883

Compare NOVN to Peers and Sector

Metrics to compare
NOVN
Peers
Sector
Relationship
P/E Ratio
17.5x17.2x−0.5x
PEG Ratio
−1.300.050.00
Price/Book
5.9x2.5x2.6x
Price / LTM Sales
4.2x2.7x3.2x
Upside (Analyst Target)
4.5%31.7%43.8%
Fair Value Upside
Unlock14.3%5.1%Unlock

Analyst Ratings

5 Buy
10 Hold
5 Sell
Ratings:
20 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 97.47
(+5.61% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 6.90%
Dividend Yield
3.79%
Annualised payout
3.50
Paid annually
5-Years Growth
+4.36%
Growth Streak

Earnings

Latest Release
Jul 17, 2025
EPS / Forecast
2.42 / 2.35
Revenue / Forecast
14.05B / 14.02B
EPS Revisions
Last 90 days

People Also Watch

83.12
SASY
-0.50%
362.55
OREP
-0.41%
1,835.500
RHMG
-0.30%
77.72
NESN
+1.21%

FAQ

What Is the Novartis (NOVN) Share Price Today?

The live Novartis share price today is 92.29

What Stock Exchange Does Novartis (NOVN) Trade On?

Novartis is listed and trades on the Switzerland Stock Exchange.

What Is the Ticker (Stock Symbol) for Novartis?

The stock symbol (also called a 'ticker') for Novartis is "NOVN."

Does Novartis Pay Dividends? What’s The Current NOVN Dividend Yield?

Yes, NOVN Pays Dividends to its Shareholders. The current Novartis dividend yield is 3.79%.

What Is the Current Novartis Market Cap?

As of today, Novartis market capitalisation is 178.66B.

What Is Novartis's (NOVN) Earnings Per Share (TTM)?

The Novartis EPS is currently 6.90 (Trailing Twelve Months).

When Is the Next Novartis Earnings Date?

Novartis's next earnings report will be released on 28 Oct 2025.

Is NOVN a Buy or Sell From a Technical Analyst Perspective?

Based on today's Novartis moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Novartis Stock Split?

Novartis has split 1 times. (See the NOVN stock split history page for full effective split date and price information.)

How Many Employees Does Novartis Have?

Novartis currently has 75883 employees.

What is the current trading status of Novartis (NOVN)?

As of 18 Jul 2025, Novartis (NOVN) is trading at a price of 92.29, with a previous close of 93.34. The stock has fluctuated within a day range of 91.94 to 93.03, while its 52-week range spans from 81.10 to 102.72.

What Is The Novartis (NOVN) Price Target According to Analysts?

The average 12-month price target for Novartis is 97.47170521, with a high estimate of 115.50852205 and a low estimate of 77.55941426. 5 analysts recommend buying the stock, while 5 suggest selling, leading to an overall rating of Neutral. The stock has an +5.61% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.